Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
Max S. Topp(European Neuroendocrine Tumor Society), Izidore S. Lossos(University of Miami), Gila Sellam(Roche (Switzerland)), Mahesh Shivhare(Roche (United Kingdom)), Tomasz Wróbel, Andreas Hochhaus(Jena University Hospital), Jan Walewski(The Maria Sklodowska-Curie National Research Institute of Oncology), Surya Chitra(Paratek Pharmaceuticals (United States)), Abraham S. Kanate(HonorHealth), Herbert Eradat(University of Colorado Cancer Center), Wanda Knopińska‐Posłuszny, Axel Florschütz(Städtisches Klinikum Dessau), Uta Brunnberg(Goethe University Frankfurt), Tina Nielsen(Roche (Switzerland)), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi)
Cited by 10
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k